This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Autism Overview
- Therapeutics Development
- Pipeline Products for Autism - Overview
- Pipeline Products for Autism - Comparative Analysis
- Autism - Therapeutics under Development by Companies
- Autism - Therapeutics under Investigation by Universities/Institutes
- Autism Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Autism - Products under Development by Companies
- Autism - Products under Investigation by Universities/Institutes
- Autism - Companies Involved in Therapeutics Development
- Addex Therapeutics Ltd
- Aequus Pharmaceuticals Inc.
- AgeneBio Inc.
- APeT Holding BV
- Berg LLC
- BioCrea GmbH
- BrainStorm Cell Therapeutics Inc.
- Cellceutix Corporation
- Confluence Pharmaceuticals LLC
- Curemark, LLC
- Domain Therapeutics SA
- F. Hoffmann-La Roche Ltd.
- Heptares Therapeutics Limited
- Intra-Cellular Therapies, Inc.
- Luc Therapeutics, Inc.
- Omeros Corporation
- Otsuka Holdings Co., Ltd.
- Retrophin Inc.
- Sage Therapeutics, Inc.
- Saniona AB
- Sumitomo Dainippon Pharma Co., Ltd.
For more information visit http://www.researchandmarkets.com/research/k4pljc/autism_pipeline